Question to the Department of Health and Social Care:

To ask His Majesty's Government whether the next review of NHS England's commercial framework for new medicines will consult on changes to the process for securing indication-specific pricing agreements for multi-indication medicines.

No formal assessment has been made. The next consultation on NHS England’s Commercial Framework, currently planned for 2026/27, will seek views on commercial options including indication-specific pricing.